NCT01977300View on ClinicalTrials.gov

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

PHASE3CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Bipolar I Disorder
Interventions
DRUG

Valproate

serum level of 50 to 125 ug/L

DRUG

Lithium

serum levels of 0.6 to 1.2 mmol/L

DRUG

Risperidone

1 to 6 mg/day

DRUG

Olanzapine

5 to 25 mg/day

OTHER

Placebo

manufactured to mimic risperidone and olanzapine

Trial Locations (1)

V6T 2A1

University of British Columbia, Vancouver

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Janssen-Ortho Inc., Canada

INDUSTRY

lead

University of British Columbia

OTHER

NCT01977300 - Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode | Biotech Hunter | Biotech Hunter